George L Bakris (G L Bakris, George Bakris)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 64

Top Venues

Diabetes, obesity & metabolism

Diabetes care

European heart journal

Journal of clinical hypertension (Greenwich, Conn.)

University of Chicago

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Chicago Aug 1o 2006

United States

Professor of medicine, Director AHA Comprehensive Hypertension Center :: Medicine

Publications

David B Sacks, Mark Arnold, George L Bakris, David E Bruns, Andrea R Horvath, Ake Lernmark, Boyd E Metzger, David M Nathan, M Sue Kirkman
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes care (2023)
George L Bakris, Cindy Chen, Alicia K Campbell, Veronica Ashton, Lloyd Haskell, Mukul Singhal
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. Journal of clinical hypertension (Greenwich, Conn.) (2023)
Nikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, Andreas Linkermann, Münevver Demir, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Ellen Burgess, Luis M Ruilope, Peter Kolkhof, Robert Lawatscheck, Charlie Scott, George L Bakris, null null
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes, obesity & metabolism (2023)
Akshay S Desai, David J Webb, Jorg Taubel, Sarah Casey, Yansong Cheng, Gabriel J Robbie, Don Foster, Stephen A Huang, Sean Rhyee, Marianne T Sweetser, George L Bakris
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. The New England journal of medicine 389 (3) (2023)
Sandra C Naaman, George L Bakris
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes care 46 (9) (2023)
Olivia Blazek, George L Bakris
Slowing the Progression of Diabetic Kidney Disease. Cells 12 (15) (2023)
Akihiko Koshino, Megumi Oshima, Clare Arnott, Robert A Fletcher, George L Bakris, Meg Jardine, Kenneth W Mahaffey, Vlado Perkovic, Carol Pollock, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, obesity & metabolism (2023)
Steven E Kahn, Cheryl A M Anderson, Mark A Atkinson, George L Bakris, John B Buse, Frank B Hu, Stephen S Rich, Matthew C Riddle, Elizabeth Selvin
Reducing Bias in Academic Publishing: The Diabetes Care Approach. Diabetes care 46 (4) (2023)
Janet B McGill, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Maria L Caramori, Meike Brinker, Amer Joseph, Andrea Lage, Robert Lawatscheck, Charlie Scott, Ellen Burgess, null null
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes, obesity & metabolism (2023)
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta Elisabeth Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George L Bakris, Tara I-Hsin Chang, Hiddo J Lambers Heerspink, Meg J Jardine, Kenneth W Mahaffey, Bruce C Neal, Carol A Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L Neuen
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. Journal of the American Heart Association (2023)
Amy Kang, Brendan Smyth, Brendon L Neuen, Hiddo J Lambers Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George L Bakris, David M Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Kenneth W Mahaffey, Vlado Perkovic, Meg J Jardine
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes, obesity & metabolism (2023)
Brendon L Neuen, Hiddo J Lambers Heerspink, Priya Vart, Brian Lee Claggett, Robert A Fletcher, Clare Arnott, Juliana de Oliveira Costa, Michael O Falster, Sallie-Anne Pearson, Kenneth W Mahaffey, Bruce C Neal, Rajiv Agarwal, George L Bakris, Vlado Perkovic, Scott D Solomon, Muthiah Vaduganathan
Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation (2023)
Janet B McGill, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, M Luiza Caramori, Meike Brinker, Amer Joseph, Andrea Lage, Robert Lawatscheck, Charlie Scott, Ellen Burgess, null null
Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes, obesity & metabolism (2023)
Nuri B Hasbal, Derek Forfang, George L Bakris, Kevin J Martin, Sharon M Moe, Stuart M Sprague
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360 (2023)
David B Sacks, Mark Arnold, George L Bakris, David E Bruns, Andrea R Horvath, Ake Lernmark, Boyd E Metzger, David M Nathan, M Sue Kirkman
Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes care (2023)
Akihiko Koshino, Megumi Oshima, Clare Arnott, Robert A Fletcher, George L Bakris, Meg Jardine, Kenneth W Mahaffey, Vlado Perkovic, Carol Pollock, Hiddo J Lambers Heerspink, Brendon L Neuen
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDENCE trial. Diabetes, obesity & metabolism (2023)
Bertram Pitt, George L Bakris
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. European heart journal (2023)
Ellen Burgess, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Liana K Billings, Jennifer B Green, Daisuke Koya, Lawrence A Leiter, Kevin M Pantalone, Christiane Ahlers, Andrea Lage, Robert Lawatscheck, Andrea Scalise, George L Bakris
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes, obesity & metabolism (2023)
Hiddo J Lambers Heerspink, Niels Jongs, Patrick Schloemer, Dustin J Little, Meike Brinker, Christoph Tasto, Martin Karpefors, David C Wheeler, George L Bakris, Vlado Perkovic, Richard Nkulikiyinka, Jerome Rossert, Samvel B Gasparyan
Development and Validation of a New Hierarchical Composite Endpoint for Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology : JASN (2023)
Jing-Wei Li, Clare Arnott, Hiddo J Lambers Heerspink, Qiang Li MBiostat, Christopher P Cannon, David C Wheeler, David M Charytan, Jennifer Barraclough, Gemma A Figtree, Rajiv Agarwal, George L Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A Pollock, Hong Zhang, Bernard Zinman, Kenneth W Mahaffey, Vlado Perkovic, Bruce C Neal, Meg J Jardine
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. Journal of the American Heart Association 11 (16) (2022)
Scott Cohen, Hillel Sternlicht, George L Bakris
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Current diabetes reports 22 (5) (2022)
Muhammad Shahzeb Khan, George L Bakris, Milton Packer, Izza Shahid, Stefan D Anker, Gregory Y H Lip, Christoph Wanner, Matthew R Weir, Faiez Zannad, Javed Butler
Kidney function assessment and endpoint ascertainment in clinical trials. European heart journal 43 (14) (2022)
Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Pieter Gillard, Richard J MacIsaac, Julio Wainstein, Amer Joseph, Meike Brinker, Lothar Roessig, Charlie Scott, George L Bakris, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null, null null
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes care 45 (4) (2022)
George L Bakris, Frederic Jaisser
Aldosterone excess and cardiorenal risk: more common than appreciated. European heart journal 43 (38) (2022)
Amir Razaghizad, Abhinav Sharma, Jiayi Ni, Joao Pedro Ferreira, William B White, Cyrus R Mehta, George L Bakris, Faiez Zannad
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial. Diabetes, obesity & metabolism (2022)
Matthew C Riddle, null null, George L Bakris, Lawrence Blonde, Andrew J M Boulton, Jessica R Castle, Linda A DiMeglio, Linda Gonder-Frederick, Frank B Hu, Steven E Kahn, Sanjay Kaul, Robert Geoffrey Moses, Stephen S Rich, Julio Rosenstock, Elizabeth Selvin, Adrian Vella, Judith Wylie-Rosett
Editorial Cycles and Continuity of Diabetes Care. Diabetes care 45 (7) (2022)
Ellen Burgess, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Vivian A Fonseca, Guillermo E Umpierrez, Maria Luiza Caramori, Amer Joseph, Marc Lambelet, Robert Lawatscheck, George L Bakris, null null
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes, obesity & metabolism (2022)
Muhammad Abdul-Ghani, George L Bakris
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes, obesity & metabolism 24 (7) (2022)
Ellen Burgess, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Janet B McGill, Sylvia E Rosas, Amer Joseph, Martin Gebel, Luke Roberts, Markus F Scheerer, George L Bakris, Rajiv Agarwal
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes care (2022)
Olivia Blazek, George L Bakris
Novel therapies on the horizon of hypertension management. American journal of hypertension (2022)
Nicholas Chiu, Rahul Aggarwal, George L Bakris, Bertram Pitt, Deepak L Bhatt
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. Journal of the American Heart Association 11 (7) (2022)
Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D Anker, Ellen Burgess, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luis M Ruilope, George L Bakris, null null
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European heart journal 43 (6) (2022)
Peter Kolkhof, Robert Lawatscheck, Gerasimos S Filippatos, George L Bakris
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. International journal of molecular sciences 23 (16) (2022)
Luis M Ruilope, Rajiv Agarwal, Stefan D Anker, Gerasimos S Filippatos, Bertram Pitt, Ellen Burgess, Pantelis A Sarafidis, Roland Erich Schmieder, Amer Joseph, Nicole Mentenich, Christina Nowack, George L Bakris, null null
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension (Dallas, Tex. : 1979) 79 (12) (2022)
J David Smeijer, Jeroen V Koomen, Donald E Kohan, John J V McMurray, George L Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Hirofumi Makino, Gert Mayer, Michal Nowicki, Vlado Perkovic, Peter Rossing, Sheldon Tobe, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clinical pharmacology and therapeutics 112 (5) (2022)
Anna M Zemke, Roger A Rodby, Martin Hertl, Ali Waleed, George L Bakris
Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3. Clinical kidney journal 15 (2) (2021)
Omar Al Dhaybi, George L Bakris
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes, obesity & metabolism (2021)
Hidehiro Kaneko, Yuichiro Yano, Hidetaka Itoh, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, George L Bakris, Katsuyuki Miura, Paul Muntner, Anthony J Viera, Suzanne Oparil, Donald M Lloyd-Jones, Hideo Yasunaga, Issei Komuro
Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. Journal of the American Heart Association 10 (22) (2021)
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Ellen Burgess, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Luis M Ruilope, null null
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine 385 (24) (2021)
Vincent D Salvador, George L Bakris
Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension (Dallas, Tex. : 1979) 78 (5) (2021)
Ahmed M Shaman, Stephen C Bain, George L Bakris, John B Buse, Thomas Idorn, Kenneth W Mahaffey, Johannes F E Mann, Michael A Nauck, Søren Rasmussen, Peter Rossing, Benjamin Wolthers, Bernard Zinman, Vlado Perkovic
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation 145 (8) (2021)
Hiddo J L Heerspink, Di Xie, George L Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Vlado Perkovic, Ellen Burgess, Hans-Henrik Parving, Dick de Zeeuw, null null
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. Journal of the American Society of Nephrology : JASN 32 (11) (2021)
Luke J Laffin, George L Bakris
Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Current cardiology reports 23 (9) (2021)
George L Bakris, Hidetaka Mikami, Masayuki Hirata, Akihiro Nakajima, Michael D Cressman
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360 2 (8) (2021)
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George L Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose Luis Gorriz Teruel, Meg J Jardine, Adeera Levin, Bruce C Neal, Luca De Nicola, Carol A Pollock, Norman Rosenthal, David C Wheeler, Kenneth W Mahaffey, Hiddo J L Heerspink
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European heart journal (2021)
Gerasimos S Filippatos, Stefan D Anker, Rajiv Agarwal, Luis M Ruilope, Peter Rossing, George L Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt, null null
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation (2021)
Clare Arnott, Jing-Wei Li, Christopher P Cannon, Dick de Zeeuw, Brendon L Neuen, Hiddo J Lambers Heerspink, David M Charytan, Anubha Agarwal, Mark D Huffman, Gemma A Figtree, George L Bakris, Tara I-Hsin Chang, Kent Feng, Norman Rosenthal, Bernard Zinman, Meg J Jardine, Vlado Perkovic, Bruce C Neal, Kenneth W Mahaffey
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes, obesity & metabolism 23 (7) (2021)
Pantelis A Sarafidis, George L Bakris
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes care 43 (8) (2021)
Peter Rossing, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Lage, Charlie Scott, George L Bakris, null null
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes, obesity & metabolism 24 (1) (2021)
Joao Pedro Ferreira, Zohra Lamiral, George L Bakris, Cyrus Mehta, William B White, Faiez Zannad
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes, obesity & metabolism 23 (7) (2021)
Nienke M A Idzerda, Lindsay E Clegg, Adrian F Hernandez, George L Bakris, Robert C Penland, David W Boulton, M Angelyn Bethel, Rury R Holman, Hiddo J Lambers Heerspink
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes, obesity & metabolism 22 (5) (2020)
Waleed Ali, George L Bakris
Evolution of Patiromer Use: a Review. Current cardiology reports 22 (9) (2020)
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, George L Bakris, Harpreet S Bajaj, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Gian Luca Di Tanna, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, Rose Qiu, Tao Sun, David C Wheeler, Hong Zhang, Bernard Zinman, Norman Rosenthal, Vlado Perkovic, null null
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology : JASN 31 (5) (2020)
Jeroen V Koomen, Jasper Stevens, George L Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John Joseph Valentine McMurray, Hans-Henrik Parving, Vlado Perkovic, Sheldon W Tobe, Dick de Zeeuw, Hiddo J Lambers Heerspink
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes, obesity & metabolism 23 (2) (2020)
M Angelyn Bethel, Robert J Mentz, Peter Merrill, John B Buse, Juliana Chung Ngor Chan, Shaun G Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D Lopes, Aldo P Maggioni, Peter Ohman, Tsvetalina Tankova, George L Bakris, Adrian F Hernandez, Rury R Holman
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes care 43 (2) (2019)
Ian H de Boer, George L Bakris
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes care 41 (4) (2018)
George L Bakris, Mark Molitch
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes care 41 (3) (2018)
Omar Al Dhaybi, George L Bakris
Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. Journal of clinical hypertension (Greenwich, Conn.) 20 (4) (2018)
George L Bakris, Lin Zhao, Stuart Kupfer, Attila Juhasz, Michie Hisada, Eric Lloyd, Suzanne Oparil
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. Journal of clinical hypertension (Greenwich, Conn.) 20 (4) (2018)
F K Dojki, George L Bakris
Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabetic medicine : a journal of the British Diabetic Association 35 (8) (2018)
Luke J Laffin, George L Bakris
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. Diabetes, obesity & metabolism 20 (6) (2018)
Hiddo J Lambers Heerspink, Dennis L Andress, George L Bakris, John J Brennan, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John Joseph Valentine McMurray, Vlado Perkovic, Sheldon Tobe, Melissa Wigderson, Tingting Yi, Hans-Henrik Parving, Dick de Zeeuw
Baseline characteristics and enrichment results from the SONAR trial. Diabetes, obesity & metabolism 20 (8) (2018)
Prakash Deedwania, Michael Weber, Paul-Egbert Reimitz, George L Bakris
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. Journal of clinical hypertension (Greenwich, Conn.) 19 (12) (2017)
Luke J Laffin, Munnam S Jafar, George L Bakris
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. Journal of clinical hypertension (Greenwich, Conn.) 19 (11) (2017)

George L Bakris.css-eqlu8i{font-size:small;padding-left:4px;} (G L Bakris, George Bakris)

Publication Activity (10 Years)

Top Topics

Top Venues

George L Bakris (G L Bakris, George Bakris)